Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors.
Jazz Pharmaceuticals Plc (JAZZ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 1,706,469 | $290,099,730 | 13.16% | |
| 2. | Millennium Management Israel Englander | 1,202,711 | $204,460,870 | +347% | 0.09% |
| 3. | AQR Capital Management Cliff Asness | 877,267 | $149,135,332 | +26% | 0.08% |
| 4. | Renaissance Technologies Jim Simons | 836,774 | $142,251,580 | -10% | 0.22% |
| 5. | GMT Capital Thomas E. Claugus | 638,500 | $108,545,000 | -20% | 5.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $103.00 | 1,621 | $166,961.54 | 101,621 | 2025-05-12 | Filing | |
| $99.71 | 100 | $9,971.00 | 100,000 | 2025-05-09 | Filing | |
| $98.91 | 19,216 | $1,900,677.62 | 99,900 | 2025-05-09 | Filing | |
| $98.10 | 80,684 | $7,915,471.55 | 80,684 | 2025-05-09 | Filing | |
| $119.65 | 12,000 | $1,435,800.00 | 27,932 | 2024-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $169.51 | 2,238 | $379,365.62 | 19,508 | 2025-12-09 | Filing | |
| $171.20 | 4,500 | $770,405.40 | 7,012 | 2025-12-05 | Filing | |
| $171.11 | 160 | $27,377.60 | 7,012 | 2025-12-05 | Filing | |
| $177.27 | 38,126 | $6,758,672.27 | 393,332 | 2025-11-26 | Filing | |
| $179.79 | 507 | $91,154.70 | 431,458 | 2025-11-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,917,142 | $1,005,914,140 | 0.01% | |
| 2. | 5,451,241 | $926,710,907 | 0.02% | |
| 3. | 2,666,602 | $453,322,340 | 0.06% | |
| 4. | 2,623,303 | $445,964,615 | 0.09% | |
| 5. | 1,837,793 | $312,424,810 | 0.01% |
News See All
Top Investors' Stock Portfolio: 10 Mid-cap Stocks To Buy
The Fed's change from higher interest rates to rate cuts has caused what Amy Y. Zhang, portfolio manager of the Alger Mid Cap 40 ETF, refers to as a "headwind to tailwind" shift in mid-cap companies.
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial
In a statement, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said that it recorded positive results for its phase 3 clinical trial for Ziihera, in combination with chemotherapy, with or without the PD-1 inhibitor...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2025 Third Quarter Earnings Conference Call.
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility.
13 Stocks With Low Beta That Can Beat Market Volatility
In August, consumer spending and income both exceeded expectations. With the relatively low rate of inflation, companies and consumers are still placing orders for costly products.
Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward trend.
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) continues to advance its mission to transform patient lives through innovative therapies for conditions with limited treatment options.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
Hedge Fund Resource Center Billionaire Hedge Funds
